Mr. Gill served as a director, president and chief executive officer of PharmAthene, Inc. from March 2015 until May 2017 and has served as a member of Altimmune’s board of directors since 2017. Mr. Gill was a founder of TetraLogic Pharmaceuticals and served as a director, president and chief executive officer from 2003 to 2013. Prior to founding TetraLogic Mr. Gill was executive vice president, chief operating officer and a director of 3-Dimensional Pharmaceuticals, a drug discovery and development company that was acquired by Johnson and Johnson during March 2003. Mr. Gill has previously held positions at SmithKline Beecham Corporation, now GlaxoSmithKline, where he served as a member of the research and development executive committee, chairman of the Research and Development Operating Committee, vice president research and development operations and finance, a founding member and partner of SR One Ltd., chief operating officer of SK&F Nova Pharmaceuticals and earlier in a variety of finance roles. Mr. Gill is a Certified Public Accountant and served in the United States Marine Corps.
